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Previous studies have shown that activation of the
Stimulator of Interferon Genes (STING) pathway is
important for regulating type I Interferons (IFN) in
tumors. Furthermore, tumor DNA induces IL-15 and IL-
15Ra mRNA in cultured dendritic cells (DC) in a STING-
dependent manner. Since we have recently shown type I
IFNs induce soluble IL-15Ra/IL-15 complexes (sIL-15
complexes), we set out to determine if sIL-15 complexes
are produced in tumor microenvironment and are regu-
lated by STING signaling. To determine if STING induces
sIL-15 complexes, mice were given STING agonists (c-di-
GMP) either i.v. or i.p. One day later, sIL-15 complexes
were increased in serum and splenic homogenates of
STING-treated mice. In addition, STING agonists directly
induced sIL-15 complexes in BM-derived DCs. To exam-
ine sIL-15 complexes in the tumor microenvironment,
B16-F10 tumors of various sizes were isolated from mice
and sIL-15 complexes were measured in homogenates
from tumors, draining lymph nodes, and spleen. Interest-
ingly, levels of sIL-15 complexes were high in homoge-
nates from small tumors (less than 100mm2) and their
draining lymph nodes but low in larger tumors. These
findings suggest IL-15 is an inflammatory factor produced
during early tumor development. To investigate the role of
IL-15 within the tumor microenvironment, we analyzed
tumor growth in mice conditionally deleted of IL-15Ra
(IL-15Ra floxed X ER-Cre Tg). Unlike IL-15Ra-/- mice,
this model system allows examination of lymphocytes that
have developed in the presence of IL-15 signals. In mice
conditionally deleted of IL-15Ra (Tamoxifen-treated IL-
15Ra floxed X ER-Cre Tg mice), tumor growth was
increased compared to control mice (Tamoxifen treated
IL-15Ra floxed mice). Overall, these studies suggest that
IL-15 is a component of the inflammatory milieu of the
tumor microenvironment that likely contributes to native
anti-tumor responses. This work was supported by a seed
fund from the Center for Inflammation and Cancer at the
MD Anderson Cancer Center and a Cancer Prevention
and Research Institute of Texas Research Training Award.
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